Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBT Margin: 2010-2024

Historic EBT Margin for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -104.58%.

  • China Pharma Holdings' EBT Margin rose 1546.00% to -86.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -78.72%, marking a year-over-year increase of 685.00%. This contributed to the annual value of -104.58% for FY2024, which is 6067.00% down from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' EBT Margin is -104.58%, which was down 138.16% from -43.91% recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' EBT Margin peaked at -26.38% during FY2020, and registered a low of -104.58% during FY2024.
  • Over the past 3 years, China Pharma Holdings' median EBT Margin value was -49.02% (recorded in 2022), while the average stood at -65.84%.
  • In the last 5 years, China Pharma Holdings' EBT Margin surged by 16,313bps in 2020 and then plummeted by 6,067bps in 2024.
  • Over the past 5 years, China Pharma Holdings' EBT Margin (Yearly) stood at -26.38% in 2020, then plummeted by 888bps to -35.26% in 2021, then plummeted by 1,377bps to -49.02% in 2022, then spiked by 511bps to -43.91% in 2023, then tumbled by 6,067bps to -104.58% in 2024.